Universiteit Gent

Vib Vzw

Ablynx N.v.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Dartmouth College

V18 Vzw

Bert Schepens

Xavier Saelens

Erik Depla

Peter Vanlandschoot

Barney S Graham

Walter C Fiers

Karen Silence

Hans De Haard

Jason Scott McLellan

Erwin Sablon

Stefan De Buck

Marie-Paule Lucienne Armanda Bouche

Mark Vaeck

Paul M P Van Bergen En Henegouwen

Iebe Rossey

Morgan Gilman

Johannes Joseph Wilhelmus De Haard

Michael John Scott Saunders

Catelijne Stortelers

Alexander Szyroki

Anna Hultberg

Jose Melero

Bram Maassen

Cornelis Theodorus Verrips

Steven Van Gucht

Robert Anthony Weiss

Nigel J Temperton

Michael Marie Harmsen

Marie-Paule Lucienne Bouche

Nigel James Temperton

The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.

Immunoglobulin single variable domain antibody against RSV prefusion F protein

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

Respiratory syncytial virus vaccine

In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Growing community of inventors

Drongen, Belgium

Bert Schepens